The inpatient satisfaction scores for the fourth quarter at Smilow Cancer Hospital were recently released and revealed significant improvements. Congratulations to NP 12, NP 14 and NP 15 for achieving a 99th percentile ranking! NP 14 had the highest mean score in YNHH with 91.4 percent overall satisfaction. NP 15 (90.3) and NP 12 (90.2) followed closely behind and NP 11 had significant gains this quarter (86.6). These high scores from our patients are a true testament to the hard work and dedication of the physicians, nurses, and staff throughout Smilow Cancer Hospital and we appreciate all of your work.
Nina Carusillo a Finalist for the Compassionate Caregiver Award from the Schwartz Center
I am proud to announce that Nina Carusillo, a PA from the Gynecologic Oncology Program, has been named one of five finalists for the 2011 Compassionate Caregiver Award from the Schwartz Center. This honor is a true testament to her dedication and care for her patients on the 14 floor of Smilow and an example of the extraordinary care that is provided to our patients each day at Smilow.
CT Challenge Survivorship Grants
We are pleased to announce that we have funding to support a third round of pilot grant funding for research in the area of cancer survivorship. Yale Cancer Center is soliciting applications for pilot grants that may provide preliminary data to support larger, national grants in survivorship research. Please note that survivorship pilot grant proposals can be submitted for both the regular YCC pilot grant program (due 11/10), as well as this specific pilot program. The application deadline is December 2, 2011. Please contact Susan Silva
for an application.
Yale Cancer Center Internal Grants Program
Yale Cancer Center is pleased to announce the 2011 Internal Grants competitions. These grants will support innovative basic, clinical, computational, prevention/control, and translational cancer research. The primary review criteria will be scientific excellence, cancer relevance, and likelihood of the project evolving into federally funded cancer research. Members of the Cancer Center or faculty who have applied for membership are eligible to apply.
Three types of grants will be awarded for one year, commencing on January 1, 2012:
of up to $50,000 for a specific project headed by a member of the Cancer Center. Up to eight Pilot Grants will support new individual research projects. Priority will be given to grants involving collaborations between two or more Cancer Center members.
Targeted Area of Research Excellence (TARE) Awards
of up to $100,000 for groups of between three and five investigators headed by a member of the Cancer Center, with the express purpose of developing a multi-investigator, basic and/or population science grant submission to the National Cancer Institute, such as a Program Project grant or Center grant. We anticipate funding up to two TARE Awards.
Translational-Targeted Area of Research Excellence (T-TARE) Awards
of up to $200,000 for groups of between three and five investigators headed by a member of the Cancer Center, for research with a significant translational or clinical component, with the express purpose of developing a multi-investigator grant submission to the National Cancer Institute, such as a Program Project Grant or SPORE grant. We anticipate funding up to two T-TARE Awards.
Deadline for Pilot Grants:
Thursday, November 10
Submission Deadline Extended for TARE and T-TARE Grants: Friday, November 18th at 4:00 PM.
Application forms and instructions for Pilot and TARE Awards may be obtained by email from Janice Zulkeski. Other questions may be emailed to Dan DiMaio.
Award application forms and instructions may be obtained by email from Julie Boyer. Other questions may be emailed to Roy Herbst.
Save the Dates
A reminder to reserve the evening of Monday, November 21 on your calendar for Yale Cancer Center's annual Conclave at the New Haven Lawn Club. Also, please plan to attend our annual holiday party on Thursday, December 15 at the Peabody Museum.
Akiko Iwasaki, PhD, a member of the YCC Molecular Virology Program, has been selected to receive the 2012 Eli Lilly and Company Research Award. Dr. Iwasaki's research focuses on innate viral recognition mechanisms and their link to adaptive immunity.
Xiwen Gu, PhD
received an American Society of Hematology (ASH) Abstract Achievement Award for
Abstract #397: The Role of DNA Repair in the Pathogenesis of Activation Induced Cytidine Deaminase Dependent B Cell Lymphoma. Dr. Gu's abstract will be presented at the ASH annual meeting in December.
Lieping Chen, PhD
has been elected to the Board of Directors of the Society for Immunotherapy of Cancer (formerly the International Society for Biological therapy of Cancer).
The Employee Profile recognizes the diverse contributions made by Yale Cancer Center and Smilow Cancer Hospital staff have to meet our patient care, research, education, and outreach goals. The staff profiled are examples of the great work being done here, and the dedication and values we possess. To suggest someone to be profiled, please contact
Peter Roche has been in his current position as Major Gifts Officer for Yale Cancer Center, as part of the Yale School of Medicine development office, for just over a year now. However, he became a part of the Yale Office of Development in 2005 as a Special Gifts Officer, and before that he worked as an Annual Giving Officer at Yale-New Haven Hospital. Through his long-standing history with Yale he has been a part of many Reunion gift campaigns, record-breaking appeals, and large donations made to support Yale.
As YCC continues to grow, so do the many opportunities for philanthropic investments.
Peter manages a portfolio of major gift prospects and donors and works closely with YCC faculty to fundraise for some of the most important endeavors, including YCC faculty research or certain disease programs.
"Most of the donors I work with have a personal connection to cancer and a strong desire to a make a difference," said Peter. "My job is to learn about their personal experiences and connect them to Yale Cancer Center in a significant and mutually beneficial way. Though everyone's experience with cancer is different, the end result is the donor's overwhelming sense of fulfillment from the meaningful investment they've made at Yale and the lives of cancer patients everywhere."
Peter's experience working with many of Yale's prominent donors and volunteers, and the relationships he has built with central development officers, helps in the effort to gain more support from Yale College alums for cancer research. His supervisor, Peter Lamothe, Director of Development for Yale Cancer Center, commented, "Peter Roche works closely with a broad range of donors that are often grateful patients and their families who wish to support Yale Cancer Center.
Of note, within the past year, Peter worked with members of the Yale Class of 1961 during their 50th Reunion year. This partnership resulted in nearly $1.5 million in current use and endowment gifts to YCC."
Thank you to Danielle Bonadies, Hari Deshpande, Mike DiGiovanna, Scott Gettinger, Stephanie Halene, Roy Herbst, Paul Jubinsky, Anthony Kim, Harriet Kluger, Sheida Mani, Miguel Materin, Mario Sznol, and Joanne Weidhaas for attending the Yale Cancer Center Grateful Patient Workshop last Friday. The session provided a solid introduction to grateful patient fundraising - explaining the many reasons patients and their families choose to make philanthropic gifts, what cues and clues to listen for that indicate possible patient interest in giving, and how to respond to their interest. If you could not attend the workshop but are interested in learning more about the program, please contact Peter Lamothe.
Free Parking is available in the Air Rights Garage. Please bring your parking ticket with you to the event.
Registration and Continental Breakfast
Welcome and Introductions
Roy S. Herbst, MD, PhD Professor of Medicine and Chief of Medical Oncology
Innovation in Lung Cancer Treatment
Daniel Boffa, MD Assistant Professor of Thoracic Surgery
Smoking Cessation and Lung Cancer Prevention
Benjamin Toll, PhD Assistant Professor of Psychiatry
Smoking Cessation Counseling and Free Nicotine Patch Medications Distributed
*Participants may be eligible for a free 2-week starter package of nicotine patch medication. You will be screened and asked to sign a consent form to assess eligibility. This promotion is available to the first 200 event participants who register.
Lymphatic Research Foundation Postdoctoral Fellowship Program
The foundation's Postdoctoral Fellowship Program is designed to support postdoctoral scientists at academic, medical, or research institutions throughout the world. The awards will support investigators who have recently received their doctorates. The goal of the fellowship program is to expand and strengthen the pool of outstanding junior investigators in the field of lymphatic research.
Projects in lymphocyte biology, leukemia, lymphoma, and conditions secondary to lymphedema such as cutaneous infections are outside the scope of this program.
Applicants must hold a PhD and/or MD or equivalent degree and have completed no more than three years of full-time postdoctoral research experience prior to the start of the grant cycle. The research project must be conducted under the supervision of a mentor who is an established investigator with an active and productive research program. The two-year fellowships provide $82,000 to $95,000 each.
Application Deadline: January 10, 2012
Melanoma Research Alliance Awards
The MRA is soliciting proposals that address the gap in translational science, i.e., turning scientific discoveries into tools and/or treatments for high-risk individuals or melanoma patients. Proposals will be accepted for Individual Investigator Awards: Young Investigator Awards, Established Investigator Awards, Pilot Awards, and Partnership Awards. Successful proposals will offer the potential for translational development that could lead to high impact near-term clinical application in areas of melanoma prevention, diagnosis, staging, and treatment.
Innovative and transforming research: Novel approaches with clear capacity to revolutionize prevention, early diagnosis, staging, or treatment for patients with melanoma or for individuals at high risk for melanoma. Transformative ideas with strong scientific rationale are encouraged.
Scientific merit: Outstanding and rigorous proposals as determined by peer review.
Potential for rapid progression to clinical testing: Proposals that articulate a clear path to clinical applicability will be strongly favored.
Application Deadline: December 1, 2011
Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ.
Cancer Biol Ther. 2011 Nov 15;12(10).
Learn More >>
Mouse melanoma models and cell lines. Damsky WE Jr, Bosenberg M.
Pigment Cell Melanoma Res. 2010 Dec;23(6):853-9.
Learn More >>
Early effects of low dose C ion or x-ray irradiation on peripheral blood lymphocytes of patients with alimentary tract cancer. Chen Y, Chen X, Li Y, Zhang H, Xie Y, Zhang X, Ren H, Wang Y, Liao S, He M, Ren J, Zhang J, Zhou X, Zheng T, Kilfoy BA, Zhang Y.
Dose Response. 2011;9(3):356-68.
Learn More >>
Molecular classification of nonsmall-cell lung cancer using a 4-protein quantitative assay. Anagnostou VK, Dimou AT, Botsis T, Killiam EJ, Gustavson MD, Homer RJ, Boffa D, Zolota V, Dougenis D, Tanoue L, Gettinger SN, Detterbeck FC, Syrigos KN, Bepler G, Rimm DL.
Cancer. 2011 Aug 25. doi: 10.1002/cncr.26450.
Learn More >>
Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM.
Biomaterials. 2011 Oct 18.
Learn More >>
Immunotherapy for metastatic melanoma. Zito C, Kluger HM.
J Cell Biochem. 2011 Oct 17. doi: 10.1002/jcb.23402.
Learn More >>
KRAS rs61764370 in Epithelial Ovarian Cancer-Response. Risch HA, Berchuck A, Paul DP; for the Ovarian Cancer Association Consortium.
Clin Cancer Res. 2011 Oct 15;17(20):6601.
Learn More >>
KRAS rs61764370 in Epithelial Ovarian Cancer-Letter. Weidhaas JB, Slack FJ.
Clin Cancer Res. 2011 Oct 15;17(20):6600.
Learn More >>
Primary tumor size, not race, determines outcomes in women with hormone-responsive breast cancer. Chagpar AB, Crutcher CR, Cornwell LB, McMasters KM.
Surgery. 2011 Oct;150(4):796-801.
Learn More >>
Psychological Distress during Ovarian Cancer Treatment: Improving Quality by Examining Patient Problems and Advanced Practice Nursing Interventions. O'Sullivan CK, Bowles KH, Jeon S, Ercolano E, McCorkle R.
Nurs Res Pract. 2011;2011:351642.
Learn More >>
Countdown to the CCSG Submission
until our CCSG
grant is due on
September 25, 2012.
Join Yale Cancer Center on Facebook
In the News
Read recent articles featuring experts from Yale Cancer Center.